Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Edoxaban (Primary)
- Indications Cardiovascular disorders; Embolism; Embolism and thrombosis; Stroke
- Focus Adverse reactions
- Acronyms ETNA-AF-EU; ETNA-AF-Europe
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
- 02 Sep 2024 Results (n=13164) assessing the clinical outcomes in frail patients with AF receiving non-rec vs recommended (rec) doses of edoxaban were published at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
- 02 Sep 2024 Results (n=13164) assessing the baseline characteristics and rates of any thromboembolic and hemorrhagic events per 100 patient-years using 4-year follow-up data, presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
- 28 Aug 2023 Results (n=13164) assessing long-term effectiveness and safety of edoxaban in patients with atrial fibrillation presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology